Opus Genetics, Inc. Common Stock IRD
Analyst Ratings
- Consensus
- Buy — 13 Buy · 0 Hold · 0 Sell (13 analysts)
- Avg. Price Target
- $11.67 (+103.6% upside)
Key Stats
- Today's Range
- $5.31 – $7.07
- 50-Day Range
- $2.82 – $7.07
- 52-Week Range
- $1.04 – $7.07
- Volume
- 54.32 million shs
- Average Volume
- 2.98 million shs
- Market Cap
- $361.07 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 1.13%
- Days to Cover
- 5.18
About Opus Genetics, Inc. Common Stock
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
Related Stocks
Compare head-to-head: IRD vs LLY·IRD vs JNJ·IRD vs ABBV·IRD vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.